HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis

BACKGROUND: Intracranial metastatic disease (IMD) is a serious and known complication of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The role of targeted therapy for patients with HER2-positive breast cancer and IMD remains unclear. In this study, we sought to evaluate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Erickson, Anders W, Ghodrati, Farinaz, Habbous, Steven, Jerzak, Katarzyna J, Sahgal, Arjun, Ahluwalia, Manmeet S, Das, Sunit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720818/
https://www.ncbi.nlm.nih.gov/pubmed/33305268
http://dx.doi.org/10.1093/noajnl/vdaa136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720818/
https://www.ncbi.nlm.nih.gov/pubmed/33305268
http://dx.doi.org/10.1093/noajnl/vdaa136

Ejemplares similares